Erwin Arief

Erwin Arief

Auto-generated profile, based on publicly available information

Erwin Arief

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia 2Department of Pulmonology, Dr. Wahidin Sudirohusodo Hospital, Makassar 90245, Indonesia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Jurnal Penyakit Dalam Indonesia
Verified
Journal Article
Open access
PDF file
ATAndi Khomeini Takdir
Andi Khomeini Takdir
EAErwin Arief
Erwin Arief
NTNur Ahmad Tabri
Nur Ahmad Tabri
ASArifin Seweng
Arifin Seweng
Hubungan Kadar Interferon-Gamma Serum dengan Derajat Kepositifan Sputum Basil Tahan Asam pada Tuberkulosis Paru Kasus Baru

29 October 2024 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
INImam Nurjaya
Imam Nurjaya
EAErwin Arief
Erwin Arief
NTNur Ahmad Tabri
Nur Ahmad Tabri
IDIrawaty Djaharuddin
Irawaty Djaharuddin
BNBulkis Natsir
Bulkis Natsir
MMMoh. Anfasa Giffari Makkaraka
Moh. Anfasa Giffari Makkaraka
Aim: Assessing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies among healthcare workers (HCWs) is crucial in understanding the durability of humoral

4 December 2023 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
AKAbdul Mubdi Aa Karim
Abdul Mubdi Aa Karim
HKHasyim Kasim
Hasyim Kasim
AAAkhyar Albaar
Akhyar Albaar
SRSitti Rabiul Zatalia Ramadhan
Sitti Rabiul Zatalia Ramadhan
NMNasrum Machmud
Nasrum Machmud
ASArifin Seweng
Arifin Seweng
Introduction: Hyperphosphatemia in chronic kidney disease (CKD) patients can stimulate the production of the fibroblast growth factor-23 (FGF-23) phosphatonin hormone, which is associated with cardiac remodeling resulting in left ventricular hypertrophy (LVH). Objectives: To determine the correlation between FGF-23 level and LVH incidence in CKD patients and establish the associated risk factors. Materials and Methods: This cross-sectional study involved 74 CKD patients who were classified as stage 3 (n=18), stage 4 (n=17), stage 3 (n=18), dialysis stage 5 (n=20), or non-dialysis stage 5 (n=19). The FGF-23 levels of the patients were measured using the ELISA (enzyme-linked immunosorbent assay) kit method, whereas a cardiologist verified LVH using an echocardiographic examination based on the LVH criteria of >95 g/m2 for females and >115 g/m2 for males. Results: A significant difference was observed in the mean FGF-23 values between the LVH and non-LVH patients (443.27±437.047 RU/mL and 172.68±185.56 RU/mL, respectively; P123.95 RU/mL had a 3.6 times greater risk of LVH compared to those with values ≤123.95 RU/mL. The LVH risk factors of gender and age, as well as hypertension, diabetes mellitus, and obesity diagnoses were not associated with LVH incidence in CKD patients. Conclusion: A significant association was found between FGF-23 level and LVH incidence in CKD patients, in which an FGF-23 level >123.95 RU/mL corresponded to a 3.6 times greater risk of LVH than those with FGF-23 levels below this value.